CLLS
Cellectis S.A.NASDAQHealthcare$3.41+0.89%ClosedMarket Cap: $341.8M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
4.74
P/S
3.55
EV/EBITDA
-9.25
DCF Value
$-5.31
FCF Yield
-16.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
83.6%
Operating Margin
-47.6%
Net Margin
-92.9%
ROE
-69.6%
ROA
-20.9%
ROIC
-17.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $10.6M | 49.8% | $-24.8M | $-26.3M | $-0.27 | — |
| FY 2025 | $73.2M | 72.5% | $-40.5M | $-67.8M | $-0.68 | — |
| Q3 2025 | $35.2M | 93.3% | $8.0M | $589.0K | $0.01 | — |
| Q2 2025 | $16.7M | 85.5% | $-9.6M | $-23.7M | $-0.24 | — |
| Q1 2025 | $10.7M | 81.1% | $-14.2M | $-18.1M | $-0.18 | — |
| Q4 2024 | $12.7M | 80.2% | $-10.7M | $5.9M | $0.06 | — |
| FY 2024 | $41.5M | 77.9% | $-59.6M | $-36.8M | $-0.41 | — |
| Q3 2024 | $16.2M | 82.8% | $-10.8M | $-23.1M | $-0.23 | — |
| Q2 2024 | $8.1M | 81.0% | $-17.2M | $-25.3M | $-0.28 | — |
| Q1 2024 | $4.5M | 48.2% | $-20.9M | $5.6M | $0.05 | — |
| Q4 2023 | $283.0K | 41.0% | $-29.6M | $-42.9M | $-0.60 | — |
| FY 2023 | $755.0K | -882.6% | $-97.3M | $-101.1M | $-1.77 | — |